News | July 21, 2025
Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
The new Zigly center features and offers comprehensive veterinary services
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
Subscribe To Our Newsletter & Stay Updated
